abstract: OBJECTIVE: To observe the effect of electroacupuncture (EA) on force-displacement value ( @entity15022 ) of muscle state and the temperature index of infrared thermogram in @entity1 with @entity121 . METHODS: @entity1 with @entity121 were randomly divided into a medication group and an EA group. The medication group (n = 60) were treated with @entity3522 dual release enteric-coated capsules, 75 mg per day for 7 days. The EA group (n = 60) received EA at bilateral Houxi (SI 3), Jiaji (EX-B2), and Ashi points, at 20-30 mm depth and 10-25 Hz frequency for 20 min daily for 7 days. Muscle states were determined by measuring FDVs of the bilateral lumbar muscle with a Myotonometer fast muscle state detector. The temperature index of the lumbar skin was measured before and after treatment with a Fluke Ti30 non-refrigerated focal plane infrared thermal imaging detector. RESULTS: There were no significant pre-treatment differences between the medication group and the EA group in mean @entity15022 (P = 0.052) or temperature index of the lumbar skin (P = 0.25). The cure rate was 63.3% in the EA group and 53.3% in the medication group. The total efficacy in the EA group (93.3 %) was not significantly different from that in the medication group (86.6 %, P = 0.204). After treatment, the mean @entity15022 of the lumbar muscle significantly increased in both groups (P < 0.05 for both groups); the @entity15022 increase in the EA group was significantly higher than in the medication group (P = 0.015). The temperature index was also significantly increased in both groups (P < 0.05 for both groups); the infrared thermogram in the EA group indicated significantly greater recovery compared to the medication group (P = 0.026). CONCLUSION: Both EA and @entity3522 markedly improved @entity697 , but EA better improved the rehabilitation and regeneration of FDVs and temperature index of infrared thermogram of the muscle.

title: Effect of electroacupuncture on muscle state and infrared thermogram changes in XXXX with @entity121 .

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: OBJECTIVE: To evaluate the effectiveness of a combined Traditional Chinese Medicine (TCM) therapy versus conventional treatment on @entity1615 . METHODS: One hundred twenty outpatients with mild and moderate @entity1615 were randomly divided into a @entity1058 ( @entity1058 ) and a brace group (CG). @entity1058 @entity1 underwent Daoyin, Tuina, and acupotomology therapies. CG @entity1 were treated with a Milwaukee brace. Each @entity1 's Cobb angle was measured after 12 and 24 months of treatment, and pulmonary function was determined after 12 months of treatment. Average electromyogram (AEMG) ratio of the surface electromyogram was measured after 6 and 12 months of treatment and followed-up after 18 and 24 months. RESULTS: The Cobb angle significantly decreased in both groups after 12 months of treatment compared with before treatment (P< 0.05). The percentages of original Cobb angle in @entity1058 and CG were 51.4% and 47.8% (P > 0.05) after 12 months and 62.5% and 34.7% (P < 0.05) after 24 months, respectively. Pulmonary function significantly improved after 12 months in @entity1058 (P < 0.05) but significantly decreased in CG (P < 0.05). The AEMG ratio was significantly lower (P < 0.01) and tended to remain at 1 after stopping treatment in @entity1058 , but increased in CG (P < 0.05). CONCLUSION: TCM combined therapy can prevent the progression of @entity1635 . The AEMG ratio is a promising index that could replace radiography in the evaluation of treatment effect and progression in @entity1635 .

title: Effect of a Traditional Chinese Medicine combined therapy on XXXX : a randomized controlled trial.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity1635 :: ('MESH:D012600', 'Disease') :: ['scoliosis']

entities_list: @entity1615 :: ('OMIM:181800', 'Disease') :: ['adolescent idiopathic scoliosis']

entities_list: @entity1058 :: ('MESH:C562377', 'Disease') :: ['TCM group', 'TCMG']

answer: @entity1615 :: (OMIM:181800,Disease) :: ['adolescent idiopathic scoliosis']


abstract: Lipoprotein lipase ( @entity14694 ) is a key enzyme in lipoprotein and adipocyte metabolism. Defects in @entity14694 can lead to @entity2298 and the subsequent development of @entity731 . The mechanisms of regulation of this enzyme are complex and may occur at multiple levels of gene expression. Because the 3'-untranslated region (UTR) is involved in @entity14694 translational regulation, @entity19 were generated with adipose tissue expression of an @entity14694 construct either with or without the proximal 3'-UTR and driven by the aP2 promoter. Both transgenic @entity19 colonies were viable and expressed the transgene, resulting in a 2-fold increase in @entity14694 activity in white adipose tissue. Neither @entity19 colony exhibited any obvious phenotype in terms of body weight, plasma lipids, @entity413 , and non-esterified @entity844 levels. In the @entity19 expressing @entity5523 with an intact 3'-UTR, @entity5523 mRNA expression approximately paralleled @entity5523 activity. However in the @entity19 without the proximal 3'-UTR, @entity5523 mRNA was low in the setting of large amounts of @entity5523 protein and @entity14694 activity. In previous studies, the 3'-UTR of @entity14694 was critical for the inhibitory effects of constitutively expressed hormones, such as thyroid hormone and @entity2661 . Therefore, these data suggest that the absence of the 3'-UTR results in a translationally unrepressed @entity14694 , resulting in a moderate overexpression of adipose @entity14694 activity.

title: XXXX expressing lipoprotein lipase in adipose tissue. Absence of the proximal 3'-untranslated region causes translational upregulation.

entities_list: @entity2298 :: ('MESH:D015228', 'Disease') :: ['hypertriglyceridemia']

entities_list: @entity844 :: ('CHEBI:35366', 'Chemical') :: ['fatty acid']

entities_list: @entity19 :: ('10090', 'Species') :: ['mice', 'mouse', 'transgenic mice']

entities_list: @entity731 :: ('MESH:D050197', 'Disease') :: ['atherosclerosis']

entities_list: @entity2661 :: ('MESH:D002395', 'Chemical') :: ['catecholamines']

entities_list: @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']

answer: @entity19 :: (10090,Species) :: ['Transgenic mice']


abstract: STUDY OBJECTIVE: To determine the feasibility of rapid pleurodesis in @entity1 with @entity3483 in order to reduce hospital length of stay in @entity1 with a limited life expectancy. DESIGN: Prospective case series. SETTING: Two university hospital programs. @entity1 : Thirty-eight @entity1 with symptomatic @entity1143 associated with @entity5 . INTERVENTIONS: @entity72276 catheter was inserted percutaneously into the pleural space after radiographic confirmation of free fluid by lateral decubitus views. Following radiographic confirmation of complete fluid evacuation, a sclerosing agent (ie, talc slurry or @entity1732 ) was instilled into the pleural space. This was accomplished within 2 h of chest tube insertion, unless the tube was inserted in the evening or if the lung was trapped. After clamping the tube for 90 min, the pleural space was drained for 2 h, after which the chest tube was removed. The intervention was scored as "successful" if no radiographic evidence of fluid reaccumulation was noted at 4 weeks. A "partial successful" score indicated reaccumulation of fluid that did not produce symptoms and did not require repeat pleural drainage of any sort. All other outcomes were scored as "unsuccessful." MEASUREMENTS AND RESULTS: Forty chest tubes were inserted into 38 @entity1 . Four procedures revealed the presence of a trapped lung and did not result in any attempt at pleurodesis. Five @entity1 who received pleurodesis died in less than 1 month and therefore were not evaluable. Two @entity1 had technical problems with the chest tube and were not evaluable. Of the remaining 29 procedures, drainage procedures with pleurodesis were performed in 27 @entity1 , a complete response was seen in 14 @entity1 (48%), a partial response was seen in 9 @entity1 (31%), and 6 @entity1 (21%) did not respond to pleurodesis. Chemical pleurodesis was completed as an outpatient procedure in only two @entity1 . In one of these, the outcome was unsuccessful. In the remainder, insertion of the chest tube in the evening or additional medical problems necessitated hospital admission, but the entire procedure was completed within 24 h. CONCLUSIONS: Chemical pleurodesis can be accomplished with good results in < 24 h in the majority of @entity1 with @entity3483 .

title: Rapid pleurodesis for XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS']

entities_list: @entity1143 :: ('MESH:D010996', 'Disease') :: ['pleural effusions']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['malignancy']

entities_list: @entity72276 :: ('p|SUB|A|14|F', 'ProteinMutation') :: ['A 14F']

entities_list: @entity1732 :: ('MESH:D001761', 'Chemical') :: ['bleomycin']

entities_list: @entity3483 :: ('MESH:D016066', 'Disease') :: ['malignant pleural effusions']

answer: @entity3483 :: (MESH:D016066,Disease) :: ['malignant pleural effusions']


abstract: OBJECTIVES: To study the difference between the disease-specific and excess mortality rate in the European Randomized Study of Screening for @entity263 section Rotterdam. METHODS: A total of 42,376 @entity1 were randomized to systematic screening or usual care. The excess number of @entity204 was defined as the difference between the observed number of @entity263 ( @entity263 ) @entity1 and the expected number of @entity204 up to 31 December 2006. The expected number was derived from mortality of all study @entity1 before a possible diagnosis with @entity263 . The disease-specific mortality rate was based on the number of @entity1 who died from @entity263 . The excess mortality rate based on the arm-specific excess number of @entity204 and the disease-specific mortality rate were compared between the two study arms. RESULTS: The overall mortality rate was not significantly different between the intervention and the control arms of the study: RR 1.02 (95% CI 0.98-1.07). The disease-specific mortality rate was 0.42 @entity1 per 1000 @entity1 -years in the intervention and 0.48 @entity1 per 1000 @entity1 -years in the control arm: RR 0.86 (95% CI 0.64-1.17). The excess mortality rate was 0.40 per 1000 @entity1 -years in the intervention arm and 0.61 @entity1 per 1000 @entity1 -years in the control arm, and the RR for excess mortality was 0.66 (95% CI 0.39-1.13). CONCLUSIONS: In contrast to the disease-specific mortality rates an increased difference in the excess mortality rates was observed between the two arms. This observation may be due to a systematic underestimation of the disease-specific @entity204 , and/or an additional disease-related mortality that is measured by an excess mortality analysis but not by a disease-specific mortality.

title: Disease-specific mortality may underestimate the total effect of XXXX screening.

entities_list: @entity1 :: ('9606', 'Species') :: ['men', 'participants', 'patients', 'person']

entities_list: @entity263 :: ('MESH:D011471', 'Disease') :: ['deaths in the prostate cancer', 'PC', 'Prostate Cancer']

answer: @entity263 :: (MESH:D011471,Disease) :: ['prostate cancer']


abstract: @entity4328 amoebae with an altered fbxA gene, which is thought to encode a component of an SCF E3 ubiquitin ligase, have defective regulation of cell type proportionality. In chimeras with wild-type cells, the mutant amoebae form mainly spores, leaving the construction of stalks to wild-type cells. To examine the role of fbxA and regulated proteolysis, we have recovered the promoter of fbxA and shown that it is expressed in a pattern resembling that of a prestalk-specific gene until late in development, when it is also expressed in developing spore cells. Because fbxA cells are developmentally deficient in pure culture, we were able to select suppressor mutations that promote sporulation of the original mutant. One suppressor mutation resides within the gene regA, which encodes a @entity1919 ( @entity268 ) phosphodiesterase linked to an activating response regulator domain. In another suppressor, there has been a disruption of dhkA, a gene encoding a two-component @entity3793 kinase known to influence @entity4328 development. RegA appears precociously and in greater amounts in the fbxA mutant than in the wild type, but in an fbxA/dhkA double mutant, RegA is restored to wild-type levels. Because the basis of regA suppression might involve alterations in @entity268 levels during development, the concentrations of @entity268 in all strains were determined. The levels of @entity268 are relatively constant during multicellular development in all strains except the dhkA mutant, in which it is reduced at least sixfold. The level of @entity268 in the double mutant dhkA/fbxA is relatively normal. The levels of @entity268 in the various mutants do not correlate with spore formation, as would be expected on the basis of our present understanding of the signaling pathway leading to the induction of spores. Altered amounts of RegA and @entity268 early in the development of the mutants suggest that both fbxA and dhkA genes act earlier than previously thought.

title: Genetic interactions of the E3 ubiquitin ligase component FbxA with XXXX metabolism and a @entity3793 kinase signaling pathway during @entity4328 development.

entities_list: @entity4328 :: ('44689', 'Species') :: ['Dictyostelium discoideum', 'Dictyostelium']

entities_list: @entity1919 :: ('MESH:D000242', 'Chemical') :: ['cyclic AMP']

entities_list: @entity3793 :: ('CHEBI:27570', 'Chemical') :: ['histidine']

answer: @entity1919 :: (MESH:D000242,Chemical) :: ['cyclic AMP']


abstract: @entity4328 amoebae with an altered fbxA gene, which is thought to encode a component of an SCF E3 ubiquitin ligase, have defective regulation of cell type proportionality. In chimeras with wild-type cells, the mutant amoebae form mainly spores, leaving the construction of stalks to wild-type cells. To examine the role of fbxA and regulated proteolysis, we have recovered the promoter of fbxA and shown that it is expressed in a pattern resembling that of a prestalk-specific gene until late in development, when it is also expressed in developing spore cells. Because fbxA cells are developmentally deficient in pure culture, we were able to select suppressor mutations that promote sporulation of the original mutant. One suppressor mutation resides within the gene regA, which encodes a @entity1919 ( @entity268 ) phosphodiesterase linked to an activating response regulator domain. In another suppressor, there has been a disruption of dhkA, a gene encoding a two-component @entity3793 kinase known to influence @entity4328 development. RegA appears precociously and in greater amounts in the fbxA mutant than in the wild type, but in an fbxA/dhkA double mutant, RegA is restored to wild-type levels. Because the basis of regA suppression might involve alterations in @entity268 levels during development, the concentrations of @entity268 in all strains were determined. The levels of @entity268 are relatively constant during multicellular development in all strains except the dhkA mutant, in which it is reduced at least sixfold. The level of @entity268 in the double mutant dhkA/fbxA is relatively normal. The levels of @entity268 in the various mutants do not correlate with spore formation, as would be expected on the basis of our present understanding of the signaling pathway leading to the induction of spores. Altered amounts of RegA and @entity268 early in the development of the mutants suggest that both fbxA and dhkA genes act earlier than previously thought.

title: Genetic interactions of the E3 ubiquitin ligase component FbxA with @entity1919 metabolism and a XXXX kinase signaling pathway during @entity4328 development.

answer: @entity3793 :: (CHEBI:27570,Chemical) :: ['histidine']


abstract: @entity4328 amoebae with an altered fbxA gene, which is thought to encode a component of an SCF E3 ubiquitin ligase, have defective regulation of cell type proportionality. In chimeras with wild-type cells, the mutant amoebae form mainly spores, leaving the construction of stalks to wild-type cells. To examine the role of fbxA and regulated proteolysis, we have recovered the promoter of fbxA and shown that it is expressed in a pattern resembling that of a prestalk-specific gene until late in development, when it is also expressed in developing spore cells. Because fbxA cells are developmentally deficient in pure culture, we were able to select suppressor mutations that promote sporulation of the original mutant. One suppressor mutation resides within the gene regA, which encodes a @entity1919 ( @entity268 ) phosphodiesterase linked to an activating response regulator domain. In another suppressor, there has been a disruption of dhkA, a gene encoding a two-component @entity3793 kinase known to influence @entity4328 development. RegA appears precociously and in greater amounts in the fbxA mutant than in the wild type, but in an fbxA/dhkA double mutant, RegA is restored to wild-type levels. Because the basis of regA suppression might involve alterations in @entity268 levels during development, the concentrations of @entity268 in all strains were determined. The levels of @entity268 are relatively constant during multicellular development in all strains except the dhkA mutant, in which it is reduced at least sixfold. The level of @entity268 in the double mutant dhkA/fbxA is relatively normal. The levels of @entity268 in the various mutants do not correlate with spore formation, as would be expected on the basis of our present understanding of the signaling pathway leading to the induction of spores. Altered amounts of RegA and @entity268 early in the development of the mutants suggest that both fbxA and dhkA genes act earlier than previously thought.

title: Genetic interactions of the E3 ubiquitin ligase component FbxA with @entity1919 metabolism and a @entity3793 kinase signaling pathway during XXXX development.

answer: @entity4328 :: (44689,Species) :: ['Dictyostelium discoideum']


abstract: Twenty-four @entity1 , ten of whom had an @entity281 due to @entity4967 -resistant, @entity9102 -sensitive bacteria, were treated with @entity9102 . A full clinical success was obtained in sixteen cases (13 @entity2885 , nine of them due to @entity4967 -resistant, @entity9102 -sensitive @entity526 , two @entity281 and one @entity55 ). Four @entity1 were improved (1 bronchiectasis, 3 @entity1778 ), three were unassessable and one failure occurred with a staphylococcal urinary tract @entity281 . A pharmacokinetic study was performed in three newborns (under three months) and ten @entity1 (mean age 3 years). @entity9102 was administered as four daily 30-min iv infusions. The mean dosage used in @entity1 under three months was 225 mg/kg/d @entity4967 and 9 mg/kg/d @entity798 . In @entity1 older than three months of age the mean dosage was 250 mg/kg/d @entity4967 and 16 mg/kg/d @entity798 . The pharmacokinetic results demonstrated similar serum concentrations of @entity4967 to those in earlier studies, and serum concentrations of @entity798 of 3.1 +/- 0.63 mg/l and 2.18 +/- 0.17 mg/ @entity72277 h respectively after infusion in newborns. For @entity1 , at the same times, the serum levels were respectively 2.3 +/- 0.9 mg/l and 1.4 +/- 0.9 mg/l. The peak serum concentrations of @entity798 were the same in the two groups of dosages (4.7 mg/l), but the half-lives of @entity798 were 1.1 h in @entity1 older than three months and 1.8 h in @entity1 younger than 3 months. The tolerance was good. @entity9102 may be useful as a first line antibiotic in infections in hospitalized @entity1 in the dosage described, as three or four injections daily, according to the age and the severity of the disease.

title: Efficacy and pharmacokinetics of XXXX in paediatric infections.

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patients', 'infants']

entities_list: @entity9102 :: ('MESH:C043215', 'Chemical') :: ['Timentin']

entities_list: @entity55 :: ('MESH:D011014', 'Disease') :: ['pneumonia']

entities_list: @entity798 :: ('MESH:D019818', 'Chemical') :: ['clavulanic acid']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['neonatal infections', 'infection']

entities_list: @entity4967 :: ('MESH:D013982', 'Chemical') :: ['ticarcillin']

entities_list: @entity1778 :: ('MESH:D007938', 'Disease') :: ['leukaemias']

entities_list: @entity2885 :: ('MESH:D011704', 'Disease') :: ['pyelonephritis']

entities_list: @entity526 :: ('562', 'Species') :: ['Escherichia coli']

answer: @entity9102 :: (MESH:C043215,Chemical) :: ['Timentin']


abstract: UNASSIGNED: Six pigment-grade (pg) or ultrafine (uf)/nanoscale (anatase and/or rutile) @entity6701 ( @entity3759 ) particulates were evaluated for in  vivo genotoxicity (OECD 474 Guidelines) in male and female @entity35 by two different laboratories. All test materials were robustly characterized. The BET surface areas of the pg and uf samples ranged from 7 to 17  m(2)/g and 50 to 82  m(2)/g respectively. The materials were assessed for induction of micronuclei and @entity137 in bone marrow by analyzing peripheral blood reticulocytes (RETs) by flow cytometry. Single oral gavage doses of 500, 1000 or 2000  mg/kg body weight (bw) of each material were implemented with concurrent negative (water) and positive controls ( @entity786 ). Approximately 48 and 72  h after exposure, blood samples were collected and 20,000 RETs per animal were analyzed. For each of the six tests, there were no biologically or toxicologically relevant increases in the micronucleated @entity35295 frequency in any @entity3759 exposed group at either time point at any dose level. In addition, there were a lack of biologically relevant decreases in %RETs among total erythrocytes. All six @entity3759 test substances were negative for in  vivo genotoxicity effects; however, it is noted that the exposure to target tissues was likely negligible. One pigment grade and one ultrafine material each were evaluated for potential systemic exposure/uptake from the gastrointestinal tract by analysis of @entity3759 into blood and liver. No significant increases in @entity3759 over controls were measured in blood (48 or 72  h) or liver (72  h) following exposures to 2000  mg/kg bw @entity3759 . These data indicate that there was no absorption of the test material from the gastrointestinal tract into the blood circulation and the lack of genotoxic effects is therefore attributed to a lack of exposure due to the inability of the test material to migrate from the gastrointestinal tract into the blood and then into target tissues.

title: In  vivo micronucleus studies with 6 XXXX materials (3  pigment-grade _ 3 nanoscale) in orally-exposed @entity35 .

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide']

entities_list: @entity6701 :: ('MESH:C009495', 'Chemical') :: ['titanium dioxide']

answer: @entity6701 :: (MESH:C009495,Chemical) :: ['titanium dioxide']


abstract: UNASSIGNED: Six pigment-grade (pg) or ultrafine (uf)/nanoscale (anatase and/or rutile) @entity6701 ( @entity3759 ) particulates were evaluated for in  vivo genotoxicity (OECD 474 Guidelines) in male and female @entity35 by two different laboratories. All test materials were robustly characterized. The BET surface areas of the pg and uf samples ranged from 7 to 17  m(2)/g and 50 to 82  m(2)/g respectively. The materials were assessed for induction of micronuclei and @entity137 in bone marrow by analyzing peripheral blood reticulocytes (RETs) by flow cytometry. Single oral gavage doses of 500, 1000 or 2000  mg/kg body weight (bw) of each material were implemented with concurrent negative (water) and positive controls ( @entity786 ). Approximately 48 and 72  h after exposure, blood samples were collected and 20,000 RETs per animal were analyzed. For each of the six tests, there were no biologically or toxicologically relevant increases in the micronucleated @entity35295 frequency in any @entity3759 exposed group at either time point at any dose level. In addition, there were a lack of biologically relevant decreases in %RETs among total erythrocytes. All six @entity3759 test substances were negative for in  vivo genotoxicity effects; however, it is noted that the exposure to target tissues was likely negligible. One pigment grade and one ultrafine material each were evaluated for potential systemic exposure/uptake from the gastrointestinal tract by analysis of @entity3759 into blood and liver. No significant increases in @entity3759 over controls were measured in blood (48 or 72  h) or liver (72  h) following exposures to 2000  mg/kg bw @entity3759 . These data indicate that there was no absorption of the test material from the gastrointestinal tract into the blood circulation and the lack of genotoxic effects is therefore attributed to a lack of exposure due to the inability of the test material to migrate from the gastrointestinal tract into the blood and then into target tissues.

title: In  vivo micronucleus studies with 6 @entity6701 materials (3  pigment-grade _ 3 nanoscale) in orally-exposed XXXX .

answer: @entity35 :: (10116,Species) :: ['rats']


abstract: OBJECTIVE: To restore islet function in @entity1 whose @entity6 subjected them to frequent dangerous episodes of hypoglycemic unawareness, and to determine whether multiple transplants are always required to achieve @entity2690 independence. SUMMARY BACKGROUND DATA: The recent report by the Edmonton group documenting restoration of @entity2690 independence by islet transplantation in seven consecutive @entity1 with type 1 @entity6 differed from previous worldwide experience of only sporadic success. In the Edmonton @entity1 , the transplanted islet mass critical for success was approximately more than 9,000 IEq/kg of recipient body weight and required two or three separate transplants of islets isolated from two to four cadaveric donors. Whether the success of the Edmonton group can be recapitulated by others, and whether repeated transplants using multiple donors will be a universal requirement for success have not been reported. METHODS: The authors report their treatment with islet transplantation of nine @entity1 whose labile type 1 @entity6 was characterized by frequent episodes of @entity4053 . RESULTS: In each of the seven @entity1 who have completed the treatment protocol (i.e., one or if necessary a second islet transplant), @entity2690 independence has been achieved. In five of the seven @entity1 only a single infusion of islets was required. To date, only one recipient has subsequently lost graft function, after an initially successful transplant. This @entity1 suffered recurrent @entity4854 9 months after the transplant. CONCLUSIONS: This report confirms the efficacy of the Edmonton immunosuppressive regimen and indicates that @entity2690 independence can often be achieved by a single transplant of sufficient islet mass.

title: XXXX independence following isolated islet transplantation and single islet infusions.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes', 'labile diabetes']

entities_list: @entity4053 :: ('MESH:D007003', 'Disease') :: ['dangerous hypoglycemia']

entities_list: @entity4854 :: ('MESH:D006943', 'Disease') :: ['hyperglycemia']

answer: @entity2690 :: (3630,Gene) :: ['Insulin']


abstract: A randomized two-stage, phase II study was conducted to assess the antitumor activity of two different schedules of topotecan in the treatment of @entity5 ( @entity151 ) in chemotherapy-naive @entity1 . A total of 40 eligible @entity1 were randomized to receive either the daily schedule, with topotecan being administered intravenously at 1.5 mg/m2 daily for 5 days every 3 weeks, or the continuous-infusion schedule, with topotecan administered intravenously at a dosage of 1.3 mg/m2 per day over 72 hours every 4 weeks. Randomization to the continuous-infusion schedule was discontinued due to inactivity, and an additional 20 @entity1 were treated on the daily schedule. @entity1 received an average of 5 courses (range: 1-13) of the daily schedule compared to an average of 2 courses (range: 1-7) of the continuous-infusion schedule (p < 0.01). Confirmed response rates for the daily and continuous-infusion schedules are 62.5% (90% CI: 49-75%) and 15% (90% CI: 1-29%), respectively. @entity137 was predominantly hematologic with 92% (55/60) having greater than or equal to grade III @entity1398 and 58% (35/60) reporting greater than or equal to grade III @entity1431 for both IV schedules. @entity137 was very mild, with only 10% (6/60) @entity1 experiencing grade IV @entity137 . One @entity1 died of @entity281 on the continuous-infusion arm. Median times to progression for the daily and continuous-infusion schedules are 5 months (90% CI: 4.4-7.2) and 2 months (90% CI: 1.1-2.1), respectively. Estimated 1-year survival rates for @entity1 receiving daily and continuous-infusion schedules are 63% (90% CI: 51-76%) and 55% (90% CI: 39-77%), respectively. Fifty percent (30/60) of @entity1 received second-line therapy with @entity2879 and @entity900 . Forty-three percent (13/30) of @entity1 who received second-line therapy achieved a confirmed response. Topotecan showed significant activity in the treatment of extensive stage @entity151 when administered as a brief daily IV repeated every 3 weeks.

title: Randomized phase II study of daily versus continuous-infusion schedules of topotecan in the treatment of XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['Nonhematologic toxicity', 'Toxicity', 'toxicities']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['extensive-stage small-cell lung cancer']

entities_list: @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin']

entities_list: @entity2879 :: ('MESH:D005047', 'Chemical') :: ['etoposide']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection']

entities_list: @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia']

entities_list: @entity1431 :: ('MESH:D007970', 'Disease') :: ['leukopenia']

answer: @entity5 :: (MESH:D009369,Disease) :: ['extensive-stage small cell lung cancers']


abstract: Some degree of peripheral @entity4 occurs in up to 20% of @entity1 treated with @entity136 (Gemzar). The @entity4 is typically mild, requiring discontinuation of the drug in less than 1% of @entity1 . Most @entity1 require no therapy. However, in cases of peripheral @entity4 , grade II or higher, suspension of @entity136 and treatment with @entity288 are often necessary, and permanent discontinuation of @entity136 may be required on occasion. We have identified 15 cases of peripheral @entity4 , grade II or greater, developing in @entity1 receiving @entity136 chemotherapy at Memorial Sloan-Kettering Cancer Center. The diagnosis was made based on temporal association with drug administration, and exclusion of other potential acute causes of @entity4 including @entity74 and @entity1150 . The 15 @entity1 in this series represent less than 1% of all @entity1 treated with @entity136 at this institution over the same time period. @entity136 was immediately discontinued at the time of the onset of @entity4 in 7 of the 15 @entity1 due to severity of the symptoms. Thirteen of the 15 @entity1 in this case series had experienced peripheral @entity4 previously, and 6 had active low-grade @entity4 at the time the @entity136 was first administered. @entity1 receiving @entity136 should be advised of this potential complication and urged to promptly report its development so that comorbid conditions can be excluded and proper supportive measures initiated. @entity1 predisposed to peripheral @entity4 from some other cause may be at increased risk for developing severe peripheral @entity4 with @entity136 .

title: XXXX -induced peripheral @entity4 : report on 15 cases and review of the literature.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity1150 :: ('MESH:D020246', 'Disease') :: ['deep vein thrombosis']

entities_list: @entity74 :: ('MESH:D030342', 'Disease') :: ['progression of disease']

entities_list: @entity136 :: ('MESH:C056507', 'Chemical') :: ['Gemcitabine', 'gemcitabine']

entities_list: @entity288 :: ('MESH:D000305', 'Chemical') :: ['corticosteroids']

answer: @entity136 :: (MESH:C056507,Chemical) :: ['Gemcitabine']


abstract: Some degree of peripheral @entity4 occurs in up to 20% of @entity1 treated with @entity136 (Gemzar). The @entity4 is typically mild, requiring discontinuation of the drug in less than 1% of @entity1 . Most @entity1 require no therapy. However, in cases of peripheral @entity4 , grade II or higher, suspension of @entity136 and treatment with @entity288 are often necessary, and permanent discontinuation of @entity136 may be required on occasion. We have identified 15 cases of peripheral @entity4 , grade II or greater, developing in @entity1 receiving @entity136 chemotherapy at Memorial Sloan-Kettering Cancer Center. The diagnosis was made based on temporal association with drug administration, and exclusion of other potential acute causes of @entity4 including @entity74 and @entity1150 . The 15 @entity1 in this series represent less than 1% of all @entity1 treated with @entity136 at this institution over the same time period. @entity136 was immediately discontinued at the time of the onset of @entity4 in 7 of the 15 @entity1 due to severity of the symptoms. Thirteen of the 15 @entity1 in this case series had experienced peripheral @entity4 previously, and 6 had active low-grade @entity4 at the time the @entity136 was first administered. @entity1 receiving @entity136 should be advised of this potential complication and urged to promptly report its development so that comorbid conditions can be excluded and proper supportive measures initiated. @entity1 predisposed to peripheral @entity4 from some other cause may be at increased risk for developing severe peripheral @entity4 with @entity136 .

title: @entity136 -induced peripheral XXXX : report on 15 cases and review of the literature.

answer: @entity4 :: (MESH:D004487,Disease) :: ['edema']


abstract: OBJECTIVE: To quantitatively evaluate a dual-modality treatment that combines autologous structural fat grafting and @entity544 ( @entity515 ) laser resurfacing for perioral and lower face rejuvenation. METHOD: Retrospective review of @entity1 undergoing rejuvenation by a single surgeon between 2005 and 2009. A blinded expert rated photographs on three scales, each with a range of 1 (no abnormality) to 5 (severe abnormality): (i) perioral fine rhytids; (ii) deep folds; and (iii) pigmentary or cutaneous abnormalities. Within-subject comparisons were generated. Results were correlated with skin type (Fitzpatrick) and baseline photodamage (Glogau). A test for effect of adjunctive procedures was performed. RESULTS: Seventeen @entity1 were included (all female, mean age 61 years). Significant postoperative improvement was noted for perioral fine rhytids (3.1 to 1.7, p < 0.0001); deep folds (3.4 to 2.0, p < 0.00001); and pigmentation (2.5 to 1.9, p = 0.02). Fitzpatrick skin type was inversely correlated with improvement in pigmentation scores (r = -0.78), while the Glogau score correlated with improvement of fine rhytids (r = 0.76). No significant effect of adjunctive procedures was found. No complications occurred, though fat grafts resorbed in one @entity1 . CONCLUSIONS: Concurrent structural fat grafting and @entity515 resurfacing result in quantifiable improvement of perioral and lower face aesthetics in relation to baseline characteristics and independent of adjunctive surgical procedures.

title: Concurrent structural fat grafting and XXXX laser resurfacing for perioral and lower face rejuvenation.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity544 :: ('MESH:D002245', 'Chemical') :: ['carbon dioxide']

answer: @entity544 :: (MESH:D002245,Chemical) :: ['carbon dioxide']


abstract: PURPOSE: We describe a novel technique of laparoscopic @entity8 with intracorporeal ice slush during partial nephrectomy as well as clinical experience with the initial 12 @entity1 . MATERIALS AND METHODS: A total of 12 select @entity1 with an infiltrating @entity703 who were candidates for nephron sparing surgery underwent transperitoneal laparoscopic partial nephrectomy with @entity8 . An Endocatch II (United States Surgical Corp., Norwalk, Connecticut) bag was placed around the mobilized kidney and its drawstring was cinched around the intact renal hilum. The renal artery and vein were occluded en bloc with a Satinsky clamp. The bottom of the engaged bag was retrieved through a 12 mm port site and opened, and ice slush was introduced within the bag to completely surround the kidney. After @entity8 was achieved laparoscopic partial nephrectomy was performed by duplicating open surgical techniques. Renal parenchymal temperature was measured using a thermocouple needle in 5 @entity1 . Median @entity5 size was 3.2 cm (range 1.5 to 5.5), 6 @entity5 (50%) were central in location and an imperative indication for partial nephrectomy was present in 7 @entity1 (58%). RESULTS: All procedures were successfully completed laparoscopically without open conversion. Median time to deploy the bag around the kidney was 7 minutes (range 5 to 20), the median volume of ice slush introduced was 600 cc (range 300 to 750) and the time needed to insert the ice slush was 4 minutes (range 3 to 10). Median @entity190 was 200 cc, total @entity63 time was 43.5 minutes (range 25 to 55) and total operative time was 4.3 hours (range 3 to 5.5). Nadir renal parenchymal temperature was 5C to 19C and the mean decrease in systemic temperature was 0.6C. Histopathology confirmed @entity1358 in 11 @entity1 (92%), of whom all had negative surgical margins. @entity3816 occurred in 2 initial @entity1 , including partial bag slippage in 1 and Satinsky clamp malfunction in 1. Postoperatively renal scan confirmed a functioning ipsilateral kidney in all cases. CONCLUSIONS: To our knowledge we present the initial clinical report of laparoscopic @entity8 for partial nephrectomy. By replicating standard open surgical practice our intracorporeal ice slush technique has the potential to extend the scope of laparoscopic partial nephrectomy to more @entity703 .

title: Laparoscopic ice slush XXXX for partial nephrectomy: the initial experience.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity8 :: ('MESH:D007674', 'Disease') :: ['renal hypothermia']

entities_list: @entity3816 :: ('MESH:D007431', 'Disease') :: ['Intraoperative complications']

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemia']

entities_list: @entity190 :: ('MESH:D006473', 'Disease') :: ['blood loss']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors']

entities_list: @entity1358 :: ('MESH:D002292', 'Disease') :: ['renal cell carcinoma']

entities_list: @entity703 :: ('MESH:D007680', 'Disease') :: ['renal tumor', 'complicated renal tumors']

answer: @entity8 :: (MESH:D007674,Disease) :: ['renal hypothermia']


abstract: MicroRNAs (miRNAs) are kind of small non-coding RNAs that negatively regulate gene expression at post-transcription level, and those non-coding RNAs appear to play a key role in tumorigenesis. The aim of this study was to investigate the biological role of @entity26365 in @entity3557 ( @entity3557 ) cell lines. We identified @entity26365 to be up-regulated in @entity3557 specimens in comparison to matched normal tissues by microRNA microarray and RT-qPCR analysis (P < 0.05). Next, to explore the potential function of @entity26365 , @entity3557 cell lines K1 and @entity15293 were transiently transfected with @entity26365 mimics and inhibitor. Successful transfection being confirmed by RT-qPCR. Ectopic expression of @entity26365 promoted proliferation and colony formation ability, and inhibited apoptosis of K1 and @entity15293 cells, whereas down-regulated expression of @entity26365 suppressed those functions when compared with the control cells. According to a computational prediction, @entity4012 maybe a potential target of @entity26365 . Luciferase assays revealed that @entity26365 is directly targeted to both binding sites of @entity4012 3'-untranslated region (3'-UTR) and suppressed the @entity4012 expression, and subsequently inhibited the expression of @entity22030 protein in @entity3557 cells. Moreover, the expression of @entity4012 had an inverse correlation with expression of @entity26365 in @entity3557 specimens by RT-qPCR and western blot analysis. The data from the present study demonstrated that @entity26365 can promote proliferation, and inhibit apoptosis in @entity3557 cell lines K1 and @entity15293 , thus @entity26365 may play an oncogenic role in @entity3557 by inhibiting the @entity4012 and regulating @entity584 / @entity4012 / @entity22030 pathway, and it may serve as a novel therapeutic target for miRNA-based @entity3557 therapy.

title: MicroRNA-96 plays an oncogenic role by targeting @entity4012 and regulating XXXX / @entity4012 / @entity22030 pathway in @entity3557 cells.

entities_list: @entity3557 :: ('MESH:C536915', 'Disease') :: ['papillary thyroid carcinoma', 'PTC']

answer: @entity584 :: (207,Gene) :: ['AKT']


abstract: MicroRNAs (miRNAs) are kind of small non-coding RNAs that negatively regulate gene expression at post-transcription level, and those non-coding RNAs appear to play a key role in tumorigenesis. The aim of this study was to investigate the biological role of @entity26365 in @entity3557 ( @entity3557 ) cell lines. We identified @entity26365 to be up-regulated in @entity3557 specimens in comparison to matched normal tissues by microRNA microarray and RT-qPCR analysis (P < 0.05). Next, to explore the potential function of @entity26365 , @entity3557 cell lines K1 and @entity15293 were transiently transfected with @entity26365 mimics and inhibitor. Successful transfection being confirmed by RT-qPCR. Ectopic expression of @entity26365 promoted proliferation and colony formation ability, and inhibited apoptosis of K1 and @entity15293 cells, whereas down-regulated expression of @entity26365 suppressed those functions when compared with the control cells. According to a computational prediction, @entity4012 maybe a potential target of @entity26365 . Luciferase assays revealed that @entity26365 is directly targeted to both binding sites of @entity4012 3'-untranslated region (3'-UTR) and suppressed the @entity4012 expression, and subsequently inhibited the expression of @entity22030 protein in @entity3557 cells. Moreover, the expression of @entity4012 had an inverse correlation with expression of @entity26365 in @entity3557 specimens by RT-qPCR and western blot analysis. The data from the present study demonstrated that @entity26365 can promote proliferation, and inhibit apoptosis in @entity3557 cell lines K1 and @entity15293 , thus @entity26365 may play an oncogenic role in @entity3557 by inhibiting the @entity4012 and regulating @entity584 / @entity4012 / @entity22030 pathway, and it may serve as a novel therapeutic target for miRNA-based @entity3557 therapy.

title: MicroRNA-96 plays an oncogenic role by targeting XXXX and regulating @entity584 / @entity4012 / @entity22030 pathway in @entity3557 cells.

answer: @entity4012 :: (2308,Gene) :: ['FOXO1']


abstract: MicroRNAs (miRNAs) are kind of small non-coding RNAs that negatively regulate gene expression at post-transcription level, and those non-coding RNAs appear to play a key role in tumorigenesis. The aim of this study was to investigate the biological role of @entity26365 in @entity3557 ( @entity3557 ) cell lines. We identified @entity26365 to be up-regulated in @entity3557 specimens in comparison to matched normal tissues by microRNA microarray and RT-qPCR analysis (P < 0.05). Next, to explore the potential function of @entity26365 , @entity3557 cell lines K1 and @entity15293 were transiently transfected with @entity26365 mimics and inhibitor. Successful transfection being confirmed by RT-qPCR. Ectopic expression of @entity26365 promoted proliferation and colony formation ability, and inhibited apoptosis of K1 and @entity15293 cells, whereas down-regulated expression of @entity26365 suppressed those functions when compared with the control cells. According to a computational prediction, @entity4012 maybe a potential target of @entity26365 . Luciferase assays revealed that @entity26365 is directly targeted to both binding sites of @entity4012 3'-untranslated region (3'-UTR) and suppressed the @entity4012 expression, and subsequently inhibited the expression of @entity22030 protein in @entity3557 cells. Moreover, the expression of @entity4012 had an inverse correlation with expression of @entity26365 in @entity3557 specimens by RT-qPCR and western blot analysis. The data from the present study demonstrated that @entity26365 can promote proliferation, and inhibit apoptosis in @entity3557 cell lines K1 and @entity15293 , thus @entity26365 may play an oncogenic role in @entity3557 by inhibiting the @entity4012 and regulating @entity584 / @entity4012 / @entity22030 pathway, and it may serve as a novel therapeutic target for miRNA-based @entity3557 therapy.

title: MicroRNA-96 plays an oncogenic role by targeting @entity4012 and regulating @entity584 / XXXX / @entity22030 pathway in @entity3557 cells.

answer: @entity4012 :: (2308,Gene) :: ['FOXO1']


abstract: MicroRNAs (miRNAs) are kind of small non-coding RNAs that negatively regulate gene expression at post-transcription level, and those non-coding RNAs appear to play a key role in tumorigenesis. The aim of this study was to investigate the biological role of @entity26365 in @entity3557 ( @entity3557 ) cell lines. We identified @entity26365 to be up-regulated in @entity3557 specimens in comparison to matched normal tissues by microRNA microarray and RT-qPCR analysis (P < 0.05). Next, to explore the potential function of @entity26365 , @entity3557 cell lines K1 and @entity15293 were transiently transfected with @entity26365 mimics and inhibitor. Successful transfection being confirmed by RT-qPCR. Ectopic expression of @entity26365 promoted proliferation and colony formation ability, and inhibited apoptosis of K1 and @entity15293 cells, whereas down-regulated expression of @entity26365 suppressed those functions when compared with the control cells. According to a computational prediction, @entity4012 maybe a potential target of @entity26365 . Luciferase assays revealed that @entity26365 is directly targeted to both binding sites of @entity4012 3'-untranslated region (3'-UTR) and suppressed the @entity4012 expression, and subsequently inhibited the expression of @entity22030 protein in @entity3557 cells. Moreover, the expression of @entity4012 had an inverse correlation with expression of @entity26365 in @entity3557 specimens by RT-qPCR and western blot analysis. The data from the present study demonstrated that @entity26365 can promote proliferation, and inhibit apoptosis in @entity3557 cell lines K1 and @entity15293 , thus @entity26365 may play an oncogenic role in @entity3557 by inhibiting the @entity4012 and regulating @entity584 / @entity4012 / @entity22030 pathway, and it may serve as a novel therapeutic target for miRNA-based @entity3557 therapy.

title: MicroRNA-96 plays an oncogenic role by targeting @entity4012 and regulating @entity584 / @entity4012 / @entity22030 pathway in XXXX cells.

answer: @entity3557 :: (MESH:C536915,Disease) :: ['papillary thyroid carcinoma']


abstract: MicroRNAs (miRNAs) are kind of small non-coding RNAs that negatively regulate gene expression at post-transcription level, and those non-coding RNAs appear to play a key role in tumorigenesis. The aim of this study was to investigate the biological role of @entity26365 in @entity3557 ( @entity3557 ) cell lines. We identified @entity26365 to be up-regulated in @entity3557 specimens in comparison to matched normal tissues by microRNA microarray and RT-qPCR analysis (P < 0.05). Next, to explore the potential function of @entity26365 , @entity3557 cell lines K1 and @entity15293 were transiently transfected with @entity26365 mimics and inhibitor. Successful transfection being confirmed by RT-qPCR. Ectopic expression of @entity26365 promoted proliferation and colony formation ability, and inhibited apoptosis of K1 and @entity15293 cells, whereas down-regulated expression of @entity26365 suppressed those functions when compared with the control cells. According to a computational prediction, @entity4012 maybe a potential target of @entity26365 . Luciferase assays revealed that @entity26365 is directly targeted to both binding sites of @entity4012 3'-untranslated region (3'-UTR) and suppressed the @entity4012 expression, and subsequently inhibited the expression of @entity22030 protein in @entity3557 cells. Moreover, the expression of @entity4012 had an inverse correlation with expression of @entity26365 in @entity3557 specimens by RT-qPCR and western blot analysis. The data from the present study demonstrated that @entity26365 can promote proliferation, and inhibit apoptosis in @entity3557 cell lines K1 and @entity15293 , thus @entity26365 may play an oncogenic role in @entity3557 by inhibiting the @entity4012 and regulating @entity584 / @entity4012 / @entity22030 pathway, and it may serve as a novel therapeutic target for miRNA-based @entity3557 therapy.

title: MicroRNA-96 plays an oncogenic role by targeting @entity4012 and regulating @entity584 / @entity4012 / XXXX pathway in @entity3557 cells.

answer: @entity22030 :: (10018,Gene) :: ['Bim']


abstract: PURPOSE: Post-radical prostatectomy @entity322 occurs in 0.5% to 87% of @entity1 . This condition may be attributable to intrinsic @entity1690 , and/or detrusor abnormalities. Previous studies of pelvic floor exercise (PFE) for improving @entity322 have shown mixed results. We determined whether preoperative and early postoperative biofeedback enhanced PFE with a dedicated physical therapist would improve the early return of @entity322 . MATERIALS AND METHODS: A total of 38 consecutive @entity1 undergoing radical prostatectomy from November 1998 to June 1999 were randomly assigned to a control or a treatment group. The treatment group of 19 @entity1 was referred to physical therapy and underwent PFE sessions before and after surgery. @entity1 were also given instructions to continue PFE at home twice daily after surgery. The control group of 19 @entity1 underwent surgery without formal PFE instructions. All @entity1 completed postoperative @entity322 at 6, 12, 16, 20, 28 and 52 weeks. @entity322 was measured by the number of pads used with 0 or 1 daily defined as continence. RESULTS: Overall 66% of the @entity1 were continent at 16 weeks. A greater fraction of the treatment group regained urinary continence earlier compared with the control group at 12 weeks (p <0.05). Three control and 2 treatment group @entity1 had severe @entity322 (greater than 3 pads daily) at 16 and 52 weeks. Of all @entity1 82% regained continence by 52 weeks. CONCLUSIONS: PFE therapy instituted prior to radical prostatectomy aids in the earlier achievement of @entity322 . However, PFE has limited benefit in @entity1 with severe @entity322 16 weeks after surgery. There is a minimal long-term benefit of PFE training since continence rates at 1 year were similar in the 2 groups.

title: The role of pelvic floor exercises on XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'men']

entities_list: @entity1690 :: ('MESH:D046628', 'Disease') :: ['sphincteric deficiency']

entities_list: @entity322 :: ('MESH:D014549', 'Disease') :: ['urinary incontinence', 'incontinence', 'urinary incontinence questionnaires', 'Incontinence', 'post-prostatectomy incontinence']

answer: @entity322 :: (MESH:D014549,Disease) :: ['post-prostatectomy incontinence']


abstract: OBJECTIVE: Since the introduction of a preformed silo to the authors' practice in 1997, there has been a decrease in primary closure of @entity6675 . To clarify the impact of this change, the authors reviewed their results over the past 10 years. METHODS: From @entity1 records, the authors abstracted the closure method, mechanical ventilation days, time to full feeds, mechanical and infectious complications, and length of stay. The authors compared groups using the Student t test and the Mann-Whitney test, as appropriate. RESULTS: Between 1993 and the present, 124 @entity1 were identified. Between 1993 and 1997, 38 @entity1 presented with @entity6675 . Thirty-two (84.2%) closures were primary and six (18.8%) were staged. After 1997, the authors treated 80 @entity1 with @entity6675 . There were 27 (33.8%) primary and 53 (66.2%) staged closures. Six @entity1 with other lethal anomalies were excluded. Length of stay and ventilator days were higher for the staged closure group, but @entity281 and mechanical complications were less common in the staged closure group. The time to full feeds did not differ. CONCLUSIONS: A lower incidence of @entity281 and complications related to @entity8479 has made staged closure of @entity6675 more common in the authors' practice. While it has resulted in a longer hospital stay, staged closure decreases the risk of long-term @entity29 and need for reoperation.

title: Evolution of staged versus primary closure of XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patients', 'patient']

entities_list: @entity29 :: ('MESH:D015212', 'Disease') :: ['bowel dysfunction']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection']

entities_list: @entity8479 :: ('MESH:D059325', 'Disease') :: ['abdominal compartment syndrome']

entities_list: @entity6675 :: ('MESH:D020139', 'Disease') :: ['gastroschisis']

answer: @entity6675 :: (MESH:D020139,Disease) :: ['gastroschisis']


abstract: OBJECTIVE: To evaluate factors predictive of survival following curative resection for node-negative @entity356 . SUMMARY BACKGROUND DATA: Presence or absence of lymph node @entity3 is the most powerful predictor of survival following curative resection for @entity356 . Factors predictive of survival in node-negative @entity356 have not been clarified. METHODS: Histopathology and clinical outcome for all @entity1 undergoing R0 resections for @entity356 at a tertiary center between 1985 and 2001 were reviewed. RESULTS: Of 1,256 R0 resections performed, 507 (40%) were node-negative, 465 were T1-T3, and 317 of these were adequately staged, as defined by histologic evaluation of at least 15 lymph nodes. Median age was 67 years, and 62% were male. Forty percent had T1 @entity5 , 34% were T2, and 26% were T3. Median @entity5 size was 3 cm. Vascular invasion (VI) was present in 17% of @entity5 and @entity3 ( @entity3 ) in 31%. Extended (D2) lymphadenectomy was performed in 75% of cases. Five- and 10-year disease-specific survival rates were 79% and 67% respectively. Factors associated with poorer disease-specific survival on univariate analysis were male gender, serosal invasion, presence of VI, presence of @entity3 , and resection other than distal subtotal gastrectomy. On multivariate analysis, @entity3 was not an independent predictor of survival, but correlated directly with advancing T stage and @entity5 size. CONCLUSIONS: Serosal invasion and presence of VI are strong predictors of poor survival in this disease. @entity3 correlates with T stage and @entity5 size and may serve as a marker of advanced disease.

title: Biologic predictors of survival in node-negative XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity356 :: ('MESH:D013274', 'Disease') :: ['gastric cancer', 'gastric adenocarcinoma']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases', 'neural invasion', 'NI']

answer: @entity356 :: (MESH:D013274,Disease) :: ['gastric cancer']


abstract: @entity27308 is a new antifolate that has shown activity in @entity1499 -resistant @entity5 . @entity136 is an antimetabolite similar in structure to @entity2592 with early studies demonstrating activity in a variety of @entity5 . It also has apparent synergistic activity with antifolates from initial work in @entity5 models. @entity1311 is an antimicrotubule agent that has a wide spectrum of activity against a variety of solid @entity5 . The combination of @entity136 , @entity1311 , and @entity27308 was assessed in this phase I trial. Thirty @entity1 were enrolled. The starting doses were @entity27308 25 mg orally twice daily (days 1-4, 15-18), @entity1311 75 mg/m2 (days 1, 15), and @entity136 750 mg/m2 (days 1, 15), which then was escalated in a stepwise fashion. Four @entity1 achieved stable disease while on study, whereas one @entity1 with a poorly differentiated @entity5 achieved a partial response. The main @entity137 was myelosuppression. The maximum tolerated dose was thought to be @entity27308 25 mg orally three times daily (days 1-4), @entity1311 150 to 175 mg/m2 (days 1, 15), and @entity136 1,000 mg/m2 (days 1, 15). The combination of these new antifolates with @entity1311 and @entity136 appears safe and should be considered for phase II trials in known @entity5 such as @entity1606 .

title: XXXX , @entity1311 , and @entity27308 : a phase I study.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'neuroendocrine tumor', 'cancers', 'responsive tumors', 'tumors']

entities_list: @entity1311 :: ('MESH:D017239', 'Chemical') :: ['paclitaxel', 'Paclitaxel']

entities_list: @entity2592 :: ('MESH:D003561', 'Chemical') :: ['cytosine arabinoside']

entities_list: @entity1606 :: ('MESH:D002295', 'Disease') :: ['transitional cell carcinomas']

entities_list: @entity27308 :: ('MESH:C024530', 'Chemical') :: ['piritrexim', 'Piritrexim']

entities_list: @entity1499 :: ('MESH:D008727', 'Chemical') :: ['methotrexate']

entities_list: @entity136 :: ('MESH:C056507', 'Chemical') :: ['Gemcitabine', 'gemcitabine']

answer: @entity136 :: (MESH:C056507,Chemical) :: ['Gemcitabine']


abstract: @entity27308 is a new antifolate that has shown activity in @entity1499 -resistant @entity5 . @entity136 is an antimetabolite similar in structure to @entity2592 with early studies demonstrating activity in a variety of @entity5 . It also has apparent synergistic activity with antifolates from initial work in @entity5 models. @entity1311 is an antimicrotubule agent that has a wide spectrum of activity against a variety of solid @entity5 . The combination of @entity136 , @entity1311 , and @entity27308 was assessed in this phase I trial. Thirty @entity1 were enrolled. The starting doses were @entity27308 25 mg orally twice daily (days 1-4, 15-18), @entity1311 75 mg/m2 (days 1, 15), and @entity136 750 mg/m2 (days 1, 15), which then was escalated in a stepwise fashion. Four @entity1 achieved stable disease while on study, whereas one @entity1 with a poorly differentiated @entity5 achieved a partial response. The main @entity137 was myelosuppression. The maximum tolerated dose was thought to be @entity27308 25 mg orally three times daily (days 1-4), @entity1311 150 to 175 mg/m2 (days 1, 15), and @entity136 1,000 mg/m2 (days 1, 15). The combination of these new antifolates with @entity1311 and @entity136 appears safe and should be considered for phase II trials in known @entity5 such as @entity1606 .

title: @entity136 , @entity1311 , and XXXX : a phase I study.

answer: @entity27308 :: (MESH:C024530,Chemical) :: ['piritrexim']


abstract: @entity27308 is a new antifolate that has shown activity in @entity1499 -resistant @entity5 . @entity136 is an antimetabolite similar in structure to @entity2592 with early studies demonstrating activity in a variety of @entity5 . It also has apparent synergistic activity with antifolates from initial work in @entity5 models. @entity1311 is an antimicrotubule agent that has a wide spectrum of activity against a variety of solid @entity5 . The combination of @entity136 , @entity1311 , and @entity27308 was assessed in this phase I trial. Thirty @entity1 were enrolled. The starting doses were @entity27308 25 mg orally twice daily (days 1-4, 15-18), @entity1311 75 mg/m2 (days 1, 15), and @entity136 750 mg/m2 (days 1, 15), which then was escalated in a stepwise fashion. Four @entity1 achieved stable disease while on study, whereas one @entity1 with a poorly differentiated @entity5 achieved a partial response. The main @entity137 was myelosuppression. The maximum tolerated dose was thought to be @entity27308 25 mg orally three times daily (days 1-4), @entity1311 150 to 175 mg/m2 (days 1, 15), and @entity136 1,000 mg/m2 (days 1, 15). The combination of these new antifolates with @entity1311 and @entity136 appears safe and should be considered for phase II trials in known @entity5 such as @entity1606 .

title: @entity136 , XXXX , and @entity27308 : a phase I study.

answer: @entity1311 :: (MESH:D017239,Chemical) :: ['Paclitaxel']


abstract: This study reports the University of Florida experience treating @entity3271 with the goal of identifying the factors that predict favorable outcome. Between 1958 and June 1998, 51 @entity1 (aged 5-75 years) were diagnosed with pure @entity3271 at the University of Florida. Histologic grade was anaplastic in 19 @entity1 , low-grade in 30 @entity1 , and unknown in one @entity1 . Twelve @entity1 were treated with surgery alone (10 with @entity5 ). Thirty-nine @entity1 underwent postoperative radiotherapy after surgery (plus chemotherapy in four @entity1 ). A biopsy was performed in 10 @entity1 , 40 underwent subtotal or gross total resection, and one had surgery of unknown extent. Thirteen @entity1 with a radiographic abnormality consistent with a @entity11 had the initiation of definitive treatment (i.e., surgery with or without radiotherapy) deferred for a median of 4.5 years before undergoing treatment for worsening symptoms or radiographic progression. Absolute survival for the entire group (51 @entity1 ) at 5, 10, and 20 years from the date of initial treatment was 61%, 37%, and 31%, respectively, and at 5, 10, and 20 years from the date of initial diagnosis was 65%, 43%, and 34%, respectively. No @entity1 died of intercurrent disease. Multivariate analysis for absolute survival from the time of initial treatment demonstrated young age (young @entity1 fared better than older @entity1 ) and size (<5 cm better than > or =5 cm) to be significant variables. No @entity1 under the age of 21 years (n = 8) at the time of diagnosis has died in this series. Deferring aggressive treatment did not alter survival. Multivariate analysis for favorable absolute survival based on the time from initial diagnosis demonstrated young age and presentation with @entity410 alone to be statistically significant for favorable outcomes. Approximately one third of @entity1 with @entity3271 appear to be cured with aggressive treatment. Age is the most important predictor of long-term progression-free and absolute survival with young @entity1 (especially aged <21 years) doing much better than older @entity1 . Deferring aggressive treatment (surgery and/or radiation) until symptoms clearly indicate @entity5 progression does not compromise outcome for a select group of @entity1 who are diagnosed at a young age with a nonenhancing mass on MR and @entity410 as the lone presenting symptom.

title: XXXX : does deferring treatment compromise outcome?

entities_list: @entity410 :: ('MESH:D012640', 'Disease') :: ['seizures']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'low-grade tumors']

entities_list: @entity11 :: ('MESH:D005910', 'Disease') :: ['low-grade glioma']

entities_list: @entity3271 :: ('MESH:D009837', 'Disease') :: ['oligodendrogliomas', 'oligodendroglioma']

answer: @entity3271 :: (MESH:D009837,Disease) :: ['Oligodendroglioma']


abstract: Anti-silencing function1 ( @entity40654 ) is an evolutionarily conserved histone chaperone. Studies in @entity375 and animals indicate that @entity40654 proteins play important roles in various chromatin-based processes, including gene transcription, DNA replication and repair. While two genes encoding @entity40654 homologues, @entity40312 and @entity40313 , are found in the @entity958 genome, their function has not been studied. Here we report that both @entity40312 and @entity40313 proteins bind histone H3, and are localized in the cytoplasm and the nucleus. Loss-of-function of either @entity40312 or @entity40313 did not show obvious defects, whereas simultaneous knockdown of both genes in the double mutant Atasf1ab drastically inhibited plant growth and caused abnormal vegetative and reproductive organ development. The Atasf1ab mutant plants exhibit cell number reduction, S-phase delay/arrest, and reduced polyploidy levels. Selective up-regulation of expression of a subset of genes, including those involved in S-phase checkpoints and the @entity17748 gene at the G   -to-M transition, was observed in Atasf1ab. Furthermore, the Atasf1ab-triggered replication fork stalling constitutively activates the DNA damage checkpoint and repair genes, including ATM, ATR, @entity72278 and @entity72279 as well as several genes of the homologous recombination (HR) pathway but not genes of the non-homologous end joining (NHEJ) pathway. In spite of the activation of repair genes, an increased level of DNA damage was detected in Atasf1ab, suggesting that defects in the mutant largely exceed the available capacity of the repair machinery. Taken together, our study establishes crucial roles for the @entity40312 and @entity40313 genes in chromatin replication, maintenance of genome integrity and cell proliferation during plant development.

title: @entity958 homologues of the histone chaperone XXXX are crucial for chromatin replication and cell proliferation in plant development.

entities_list: @entity958 :: ('3702', 'Species') :: ['Arabidopsis']

answer: @entity40654 :: (853327(Tax:4932),Gene) :: ['ASF1']


abstract: Anti-silencing function1 ( @entity40654 ) is an evolutionarily conserved histone chaperone. Studies in @entity375 and animals indicate that @entity40654 proteins play important roles in various chromatin-based processes, including gene transcription, DNA replication and repair. While two genes encoding @entity40654 homologues, @entity40312 and @entity40313 , are found in the @entity958 genome, their function has not been studied. Here we report that both @entity40312 and @entity40313 proteins bind histone H3, and are localized in the cytoplasm and the nucleus. Loss-of-function of either @entity40312 or @entity40313 did not show obvious defects, whereas simultaneous knockdown of both genes in the double mutant Atasf1ab drastically inhibited plant growth and caused abnormal vegetative and reproductive organ development. The Atasf1ab mutant plants exhibit cell number reduction, S-phase delay/arrest, and reduced polyploidy levels. Selective up-regulation of expression of a subset of genes, including those involved in S-phase checkpoints and the @entity17748 gene at the G   -to-M transition, was observed in Atasf1ab. Furthermore, the Atasf1ab-triggered replication fork stalling constitutively activates the DNA damage checkpoint and repair genes, including ATM, ATR, @entity72278 and @entity72279 as well as several genes of the homologous recombination (HR) pathway but not genes of the non-homologous end joining (NHEJ) pathway. In spite of the activation of repair genes, an increased level of DNA damage was detected in Atasf1ab, suggesting that defects in the mutant largely exceed the available capacity of the repair machinery. Taken together, our study establishes crucial roles for the @entity40312 and @entity40313 genes in chromatin replication, maintenance of genome integrity and cell proliferation during plant development.

title: XXXX homologues of the histone chaperone @entity40654 are crucial for chromatin replication and cell proliferation in plant development.

answer: @entity958 :: (3702,Species) :: ['Arabidopsis']


abstract: PURPOSE: Although many aspects of ureteral physiology are well characterized, the exact mechanism of ureteral smooth muscle modulation has not been fully established. In other smooth muscle contractility is modulated by @entity2178 ( @entity2178 ). We determined the presence of a local ureteral @entity916 -angiotensin system and characterized the functional role of @entity2178 in ureteral smooth muscle. MATERIALS AND METHODS: Reverse transcriptase-polymerase chain reaction was performed to determine the expression of @entity2178 , @entity916 , angiotensin-converting enzyme and angiotensin receptor subtype 1 mRNA. The presence of @entity2178 in ureteral tissue was determined by immunohistochemistry. @entity1 and @entity1707 ureteral smooth muscle strips were suspended in tissue baths to determine the effect of the @entity2178 receptor antagonist @entity9886 on the frequency and amplitude of spontaneous ureteral contractions. Electrical field stimulation was performed before and after exposure to @entity9886 . RESULTS: @entity2178 , @entity916 , angiotensin-converting enzyme and angiotensin receptor subtype 1 mRNA expression was detected in @entity1 ureter. Immunoreactivity for @entity2178 was demonstrated in smooth muscle bundles and blood vessels of the ureter. @entity9886 decreased the amplitude and frequency of spontaneous ureteral contractions as well as the contractile response to electrical field stimulation in a dose dependent manner. CONCLUSIONS: Gene expression of @entity2178 precursors and receptor, and localization of @entity2178 in the ureter suggest the presence of a local @entity916 -angiotensin system in the ureter. The effect of @entity2178 receptor antagonist on contractile responses suggests that @entity2178 modulates ureteral smooth muscle contractile function. Therefore, a local @entity916 -angiotensin system may have an important role in ureteral function under physiological and pathological conditions.

title: Ureteral function is modulated by a local XXXX -angiotensin system.

entities_list: @entity2178 :: ('183', 'Gene') :: ['angiotensin II', 'angiotensinogen', 'Angiotensinogen', 'AngII']

entities_list: @entity9886 :: ('MESH:D019808', 'Chemical') :: ['losartan', 'Losartan']

answer: @entity916 :: (5972,Gene) :: ['renin']


abstract: @entity8 ( @entity359 ) with @entity2785 (AMLEC) is a comparatively rare @entity703 that is recently recognized as a distinct entity and there are relatively few reported cases in the English-language literature. To date 19 cases of AMLEC have been reported in 2 case series and a few case reports. AMLEC has been described as a cystic variant of @entity359 . Herein we reported an AMLEC in a 25-year-old female @entity1 , and to the best of our knowledge this is the first case report of AMLEC in Chinese. She was incidentally found to have a kidney-occupying lesion during a routine medical examination for 1 month. CT examination demonstrated a @entity54790 arising from right-kidney lower pole. The @entity1 underwent the partial nephrectomy. Histological examination of the @entity5 was composed of @entity2785 , @entity8165 and muscle-predominant @entity359 . Immunohistochemically, @entity2785 were positive for CK but negative for ER, PR, @entity2282 and HMB-45; the subepithelial stroma and muscle-predominant @entity359 were positive for ER, PR and HMB-45; the subepithelial stroma was negative for @entity4574 , but muscle-predominant @entity359 was positive for @entity4574 . The final histopathological diagnosis was AMLEC.

title: XXXX with @entity2785 : a rare entity and review of literature.

entities_list: @entity8165 :: ('MESH:C567547', 'Disease') :: ['compact subepithelial mullerian-like stroma']

entities_list: @entity8 :: ('MESH:D007674', 'Disease') :: ['Renal angiomyolipoma']

entities_list: @entity2785 :: ('MESH:D009375', 'Disease') :: ['epithelial cysts']

entities_list: @entity54790 :: ('MESH:D002636', 'Disease') :: ['multilocular cystic lesions']

entities_list: @entity703 :: ('MESH:D007680', 'Disease') :: ['benign renal tumor']

answer: @entity8 :: (MESH:D007674,Disease) :: ['Renal angiomyolipoma']


abstract: @entity8 ( @entity359 ) with @entity2785 (AMLEC) is a comparatively rare @entity703 that is recently recognized as a distinct entity and there are relatively few reported cases in the English-language literature. To date 19 cases of AMLEC have been reported in 2 case series and a few case reports. AMLEC has been described as a cystic variant of @entity359 . Herein we reported an AMLEC in a 25-year-old female @entity1 , and to the best of our knowledge this is the first case report of AMLEC in Chinese. She was incidentally found to have a kidney-occupying lesion during a routine medical examination for 1 month. CT examination demonstrated a @entity54790 arising from right-kidney lower pole. The @entity1 underwent the partial nephrectomy. Histological examination of the @entity5 was composed of @entity2785 , @entity8165 and muscle-predominant @entity359 . Immunohistochemically, @entity2785 were positive for CK but negative for ER, PR, @entity2282 and HMB-45; the subepithelial stroma and muscle-predominant @entity359 were positive for ER, PR and HMB-45; the subepithelial stroma was negative for @entity4574 , but muscle-predominant @entity359 was positive for @entity4574 . The final histopathological diagnosis was AMLEC.

title: @entity8 with XXXX : a rare entity and review of literature.

answer: @entity2785 :: (MESH:D009375,Disease) :: ['epithelial cysts']


abstract: What's known on the subject? and What does the study add? The side-effect of targeted agents is known. The clinician should be aware of the side-effects of targeted agents and how to prevent/diminish them, particularly in sequential and combination therapies. The aim of this review is to help physicians tailor targeted treatments for @entity1358 to suit @entity1 needs and ensure maximum overall duration of response to therapy by providing a summary of the frequency and time of onset of adverse events (AEs) and by raising awareness of AE profiles. A PubMed literature search was performed, and papers on targeted therapy-related AEs were reviewed. The frequency, severity and management of targeted therapy-related AEs are discussed. Manageable AEs commonly reported with all the approved targeted agents include: fatigue, @entity344 ( @entity294 , @entity390 , @entity391 ), @entity101 , skin and @entity3145 . Life-threatening AEs are less common than manageable AEs and are usually class specific. Data suggest that long-term treatment with well-established targeted agents does not result in increased or unexpected AEs. Caution is required with regard to the long-term use of newer targeted agents for which there are no long-term tolerability data or clinical experience. Studies have reported that the type and frequency of observed AEs associated with sequential @entity669 kinase inhibitor (TKI) use are similar to those reported in the literature for TKI monotherapy. Having an awareness of the AE profiles of targeted agents allows the development of effective management strategies. Generally, more extensive clinical experience has accumulated, and AE profiles are more predictable, for well-established targeted agents.

title: Adverse events from targeted therapies in XXXX : the impact on long-term use.

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension']

entities_list: @entity3145 :: ('MESH:D017695', 'Disease') :: ['subcutaneous tissue disorders']

entities_list: @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhoea']

entities_list: @entity391 :: ('MESH:D014839', 'Disease') :: ['vomiting']

entities_list: @entity344 :: ('MESH:D005767', 'Disease') :: ['gastrointestinal disorders']

entities_list: @entity1358 :: ('MESH:D002292', 'Disease') :: ['advanced renal cell carcinoma']

entities_list: @entity669 :: ('CHEBI:18186', 'Chemical') :: ['tyrosine']

answer: @entity1358 :: (MESH:D002292,Disease) :: ['advanced renal cell carcinoma']


abstract: BACKGROUND: Development of neutralizing anti-factor (F)VIII antibodies ('inhibitors') is a serious clinical problem in @entity447 . Increased inhibitor risk has been associated with certain @entity2801 missense substitutions, including @entity72280 in the A2 domain. OBJECTIVES: The aim of the present study was to identify T-cell epitopes in @entity2801 and characterize T-cell responses in two unrelated @entity447 subjects sharing F8- @entity72280 and @entity1533 *1101 genotypes. We hypothesized that the hemophilic substitution site coincides with an important T-cell epitope. @entity1 /METHODS: The binding affinities of peptides for recombinant HLA-DR proteins were measured and compared with epitope prediction results. CD4+ T cells were stimulated using peptides and stained with fluorescent, peptide-loaded tetramers. RESULTS: The inhibitor subjects, but not HLA-matched controls, had high-avidity @entity1533 *1101-restricted T-cell responses against @entity2801 (589-608), which contains the hemophilic missense site. Antigen-specific T cells secreted @entity1198 and Th2 cytokines and proliferated in response to @entity2801 and @entity2801 (592-603). @entity2801 (589-608) bound with physiologically relevant (micromolar) IC(50) values to recombinant DR0101, DR1101 and DR1501 proteins. CONCLUSIONS: @entity447 @entity1 with @entity72280 missense substitutions and these HLA haplotypes had an increased incidence of inhibitors in our cohorts, supporting a paradigm in which presentation of @entity2801 epitopes containing the wild-type R593 influences inhibitor risk in this @entity447 sub-population.

title: T-cell responses in two unrelated XXXX inhibitor subjects include an epitope at the factor VIII @entity72280 missense site.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS']

entities_list: @entity447 :: ('MESH:D006467', 'Disease') :: ['Hemophilia A', 'hemophilia A']

answer: @entity447 :: (MESH:D006467,Disease) :: ['hemophilia A']


abstract: BACKGROUND: Development of neutralizing anti-factor (F)VIII antibodies ('inhibitors') is a serious clinical problem in @entity447 . Increased inhibitor risk has been associated with certain @entity2801 missense substitutions, including @entity72280 in the A2 domain. OBJECTIVES: The aim of the present study was to identify T-cell epitopes in @entity2801 and characterize T-cell responses in two unrelated @entity447 subjects sharing F8- @entity72280 and @entity1533 *1101 genotypes. We hypothesized that the hemophilic substitution site coincides with an important T-cell epitope. @entity1 /METHODS: The binding affinities of peptides for recombinant HLA-DR proteins were measured and compared with epitope prediction results. CD4+ T cells were stimulated using peptides and stained with fluorescent, peptide-loaded tetramers. RESULTS: The inhibitor subjects, but not HLA-matched controls, had high-avidity @entity1533 *1101-restricted T-cell responses against @entity2801 (589-608), which contains the hemophilic missense site. Antigen-specific T cells secreted @entity1198 and Th2 cytokines and proliferated in response to @entity2801 and @entity2801 (592-603). @entity2801 (589-608) bound with physiologically relevant (micromolar) IC(50) values to recombinant DR0101, DR1101 and DR1501 proteins. CONCLUSIONS: @entity447 @entity1 with @entity72280 missense substitutions and these HLA haplotypes had an increased incidence of inhibitors in our cohorts, supporting a paradigm in which presentation of @entity2801 epitopes containing the wild-type R593 influences inhibitor risk in this @entity447 sub-population.

title: T-cell responses in two unrelated @entity447 inhibitor subjects include an epitope at the factor VIII XXXX missense site.

answer: @entity72280 :: (p|SUB|R|593|C,ProteinMutation) :: ['R593C']


abstract: Botulinum toxin has meanwhile been approved for a number of indications. It is also gaining acceptance in other indications with a major focus on @entity158 . The most common type of @entity10 is @entity2701 ( @entity2701 ) the pathogenesis of which has not yet been unfolded. As it looks there are vascular, myofascial and supraspinal factors intertwined. It is felt that @entity10 is triggered by myofascial stimuli. The application of botulinum toxin is an intelligent alternative since the favorable effect of pharmacologic and other therapies is limited. Application of BTX should be considered when the pericranial muscles are involved. One of the effects produced lies in the @entity121 , muscular @entity63 and muscle tone. We still don't know whether additional mechanisms such as retrograde uptake and direct antiinflammatory potential are involved. Current data permit the conclusion that headaches are decreased in their frequency and distinctiveness. Significant untoward effects are not to be expected. Neither the ideal dose nor the optimum selection of injection sites have been established as yet, an individual injection scheme is apparently most promising. Injection of the trigger points seems to make sense.

title: [Botulinum toxin in XXXX ].

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemia']

entities_list: @entity2701 :: ('MESH:D018781', 'Disease') :: ['tension-type headache', 'TTH']

entities_list: @entity10 :: ('MESH:D006261', 'Disease') :: ['headache']

entities_list: @entity121 :: ('MESH:D009135', 'Disease') :: ['reduction of muscular stress']

answer: @entity2701 :: (MESH:D018781,Disease) :: ['tension-type headache']


abstract: This case report describes the first reported @entity1445 of the dihydropyridine @entity460 channel blocker (CCB) @entity50664 . A 49 yr old male presented to the Emergency Department 3 hrs after the ingestion of 560 mg of @entity50664 . In the department he had a witnessed @entity410 within 15 minutes of arrival attributed to the @entity1445 . Following immediate recovery of consciousness after the @entity410 , he had refractory @entity551 and @entity1168 which failed to respond to fluid resuscitation, glucagon therapy, and intravenous @entity460 . He went on to require vasopressor support with noradrenaline and was treated with high dose insulin therapy which was successful in achieving cardiovascular stability. Vasopressor therapy was no longer required within one half life of @entity50664 , and the total stay on intensive care was one day before transfer to a ward. @entity460 channel blocker @entity1445 is an uncommon but life-threatening @entity1445 . Treatment for severe @entity137 is similar to b-blocker @entity1445 . @entity551 is treated with intravenous fluid therapy, intravenous @entity460 and possibly glucagon with vasopressor or inotropic support as required. @entity3897 is used to attempt reversal of @entity1168 . High doses of intravenous insulin with intravenous dextrose as required (hyperinsulinaemic euglycaemia or HIET), has also been successfully reported. Experimental animal data suggests that HIET is of benefit and potentially superior to fluid therapy, @entity460 , glucagon and potentially vasopressor therapy. HIET effectively and sustainably reverses @entity551 , @entity1168 and improves myocardial contractility and metabolism. Current advice in @entity460 channel blocker @entity1445 is to begin therapy early in @entity137 , starting with a 1.0 IU/kg insulin bolus followed by an infusion of 0.5 IU/kg/hr of insulin and dextrose as required titrated to clinical response.

title: Management of @entity50664 XXXX with hyperinsulinaemic euglycaemia therapy: case report.

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity1168 :: ('MESH:D001919', 'Disease') :: ['bradycardia']

entities_list: @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium', 'Calcium']

entities_list: @entity3897 :: ('MESH:D001285', 'Chemical') :: ['Atropine']

entities_list: @entity50664 :: ('MESH:C060343', 'Chemical') :: ['lercanidipine']

entities_list: @entity551 :: ('MESH:D007022', 'Disease') :: ['Hypotension', 'hypotension']

answer: @entity1445 :: (MESH:D062787,Disease) :: ['overdose']


abstract: This case report describes the first reported @entity1445 of the dihydropyridine @entity460 channel blocker (CCB) @entity50664 . A 49 yr old male presented to the Emergency Department 3 hrs after the ingestion of 560 mg of @entity50664 . In the department he had a witnessed @entity410 within 15 minutes of arrival attributed to the @entity1445 . Following immediate recovery of consciousness after the @entity410 , he had refractory @entity551 and @entity1168 which failed to respond to fluid resuscitation, glucagon therapy, and intravenous @entity460 . He went on to require vasopressor support with noradrenaline and was treated with high dose insulin therapy which was successful in achieving cardiovascular stability. Vasopressor therapy was no longer required within one half life of @entity50664 , and the total stay on intensive care was one day before transfer to a ward. @entity460 channel blocker @entity1445 is an uncommon but life-threatening @entity1445 . Treatment for severe @entity137 is similar to b-blocker @entity1445 . @entity551 is treated with intravenous fluid therapy, intravenous @entity460 and possibly glucagon with vasopressor or inotropic support as required. @entity3897 is used to attempt reversal of @entity1168 . High doses of intravenous insulin with intravenous dextrose as required (hyperinsulinaemic euglycaemia or HIET), has also been successfully reported. Experimental animal data suggests that HIET is of benefit and potentially superior to fluid therapy, @entity460 , glucagon and potentially vasopressor therapy. HIET effectively and sustainably reverses @entity551 , @entity1168 and improves myocardial contractility and metabolism. Current advice in @entity460 channel blocker @entity1445 is to begin therapy early in @entity137 , starting with a 1.0 IU/kg insulin bolus followed by an infusion of 0.5 IU/kg/hr of insulin and dextrose as required titrated to clinical response.

title: Management of XXXX @entity1445 with hyperinsulinaemic euglycaemia therapy: case report.

answer: @entity50664 :: (MESH:C060343,Chemical) :: ['lercanidipine']


abstract: A 43-year-old @entity1 presented with a widespread @entity2631 , which had its onset three months before. The @entity1 had several plaques of active, pigmented, lilac halo disease on the trunk, arms and thighs. A biopsy confirmed that the @entity1 was suffering from @entity2631 . Therapy with @entity6914 ointment 0.05% was introduced, applied twice a day, 5 days a week. After a month, the ointment failed to significantly improve the lesions. Then the @entity1 was treated with @entity6914 ointment in the morning and @entity56593 ointment 4 mcg/g in the evening. This combination resulted in marked improvement of the disease after 20 days of therapy, and we decided to stop topical @entity134 . After three months of treatment with topical @entity56593 once a day, the plaques regressed considerably and only a very slight pigmentation remained. Therapy was further reduced to one evening, every other day for six months more, and then was suspended completely. No side effects were observed and there was no recurrence at 24-month follow up.

title: Biopsy proven XXXX treated with @entity56593 ointment: case report.

entities_list: @entity1 :: ('9606', 'Species') :: ['woman', 'patient']

entities_list: @entity134 :: ('CHEBI:35341', 'Chemical') :: ['steroid']

entities_list: @entity6914 :: ('MESH:D002990', 'Chemical') :: ['clobetasol propionate', 'clobetasol']

entities_list: @entity56593 :: ('MESH:C023850', 'Chemical') :: ['tacalcitol']

answer: @entity2631 :: (MESH:D012594,Disease) :: ['morphea']


abstract: A 43-year-old @entity1 presented with a widespread @entity2631 , which had its onset three months before. The @entity1 had several plaques of active, pigmented, lilac halo disease on the trunk, arms and thighs. A biopsy confirmed that the @entity1 was suffering from @entity2631 . Therapy with @entity6914 ointment 0.05% was introduced, applied twice a day, 5 days a week. After a month, the ointment failed to significantly improve the lesions. Then the @entity1 was treated with @entity6914 ointment in the morning and @entity56593 ointment 4 mcg/g in the evening. This combination resulted in marked improvement of the disease after 20 days of therapy, and we decided to stop topical @entity134 . After three months of treatment with topical @entity56593 once a day, the plaques regressed considerably and only a very slight pigmentation remained. Therapy was further reduced to one evening, every other day for six months more, and then was suspended completely. No side effects were observed and there was no recurrence at 24-month follow up.

title: Biopsy proven @entity2631 treated with XXXX ointment: case report.

answer: @entity56593 :: (MESH:C023850,Chemical) :: ['tacalcitol']


abstract: BACKGROUND: The significance of mild elevations in cardiac enzymes after an elective percutaneous coronary intervention (PCI) still remains controversial. We evaluated the significance of @entity908 phosphokinase level (CPK) elevations in a large cohort of @entity1 who had undergone an elective PCI before the IIb/IIIa receptor antagonist era. METHODS: All @entity1 enrolled in the Emory databank from 1981 to 1996 who had an elective PCI were evaluated. We identified 15,637 @entity1 who met our inclusion and exclusion criteria. @entity1 were divided into 4 groups on the basis of the magnitude of the CPK elevation noted in the post-PCI period: group I (CPK <250 mg/dL, n = 14,512); group II (CPK 250-500 mg/dL, n = 715); group III (CPK 500-750 mg/dL, n = 164); and group IV (CPK >750 mg/dL, n = 246). RESULTS: CPK elevations were associated with a significant increase in the periprocedure angiographic complications. Angiographic complication rates were 14.6%, 30.5%, 40.2%, and 43.5% in groups I, II, III, and IV, respectively (P <.001). Long-term survival also correlated inversely with the magnitude of CPK elevations. The 10-year survival rates were 73%, 71%, 69%, and 55% in groups I, II, III, and IV, respectively (P <.0001). After multivariate analysis to correct for clinical factors, a CPK elevation of at least 3-times normal (group IV) was found to be an independent predictor of diminished 30-day and long-term survival (hazard ratio 1.84, 95% CI 1.41-2.41, P <.0001). Elevations in CPK <3-times normal (groups II and III) were not independently predictive of poor long-term survival. CONCLUSION: A CPK level >3-times normal after an elective PCI is a strong independent predictor of poor long-term prognosis.

title: Prognostic implication of XXXX kinase release after elective percutaneous coronary intervention in the pre-IIb/IIIa antagonist era.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'Patients']

entities_list: @entity908 :: ('MESH:D003401', 'Chemical') :: ['creatine']

answer: @entity908 :: (MESH:D003401,Chemical) :: ['creatine']


abstract: This is a retrospective analysis of 188 @entity1 who underwent @entity348 ( @entity348 ) in one or two fractions before bone marrow transplantation (BMT) for a @entity1503 . While 139 @entity1 had eye shielding during @entity348 to decrease @entity231 formation, 49 did not. The blocks used for shielding caused cylindrical areas of decreased dose intensity in the brain. The aim of the study was to determine if there was an increased risk of @entity735 or in the CNS after shielding of the eyes. The probability and severity of @entity231 formation with and without shielding were also evaluated. None of the 49 @entity1 without shielding had a relapse in their eyes or in the CNS after BMT. Of the @entity1 with shielding, none had a @entity735 but two of the 139 (1.4%) had a CNS relapse. The incidence of @entity231 without shielding was 90% (19 of 21 evaluable @entity1 ), while with shielding it was 31% (20 of 64). Severe @entity231 were present in eight of 21 (38%) @entity1 without and two of 64 (3%) @entity1 with shielding. The probability of staying @entity231 free for at least five years was 0.77 with and 0.33 without shielding, at 8 years it was 0.53 and 0.24 respectively. The relative risk of developing a @entity231 without shielding vs shielding was three (95% CI=1.5; 5.9). It appears that the incidence of @entity735 and CNS is not increased when the eyes are shielded during @entity348 . Shielding increased the latency time of @entity231 formation and decreased the severity of @entity231 .

title: Eye shielding during XXXX for bone marrow transplantation in @entity1 transplanted for a @entity1503 : risks and benefits.

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patients']

entities_list: @entity231 :: ('MESH:D002386', 'Disease') :: ['cataracts', 'cataract']

entities_list: @entity1503 :: ('MESH:D006402', 'Disease') :: ['hematological disorder']

entities_list: @entity735 :: ('MESH:D005124', 'Disease') :: ['relapse in the eyes']

entities_list: @entity348 :: ('MESH:C535338', 'Disease') :: ['TBI', 'total body irradiation']

answer: @entity348 :: (MESH:C535338,Disease) :: ['total body irradiation']


abstract: This is a retrospective analysis of 188 @entity1 who underwent @entity348 ( @entity348 ) in one or two fractions before bone marrow transplantation (BMT) for a @entity1503 . While 139 @entity1 had eye shielding during @entity348 to decrease @entity231 formation, 49 did not. The blocks used for shielding caused cylindrical areas of decreased dose intensity in the brain. The aim of the study was to determine if there was an increased risk of @entity735 or in the CNS after shielding of the eyes. The probability and severity of @entity231 formation with and without shielding were also evaluated. None of the 49 @entity1 without shielding had a relapse in their eyes or in the CNS after BMT. Of the @entity1 with shielding, none had a @entity735 but two of the 139 (1.4%) had a CNS relapse. The incidence of @entity231 without shielding was 90% (19 of 21 evaluable @entity1 ), while with shielding it was 31% (20 of 64). Severe @entity231 were present in eight of 21 (38%) @entity1 without and two of 64 (3%) @entity1 with shielding. The probability of staying @entity231 free for at least five years was 0.77 with and 0.33 without shielding, at 8 years it was 0.53 and 0.24 respectively. The relative risk of developing a @entity231 without shielding vs shielding was three (95% CI=1.5; 5.9). It appears that the incidence of @entity735 and CNS is not increased when the eyes are shielded during @entity348 . Shielding increased the latency time of @entity231 formation and decreased the severity of @entity231 .

title: Eye shielding during @entity348 for bone marrow transplantation in @entity1 transplanted for a XXXX : risks and benefits.

answer: @entity1503 :: (MESH:D006402,Disease) :: ['hematological disorder']


abstract: This is a retrospective analysis of 188 @entity1 who underwent @entity348 ( @entity348 ) in one or two fractions before bone marrow transplantation (BMT) for a @entity1503 . While 139 @entity1 had eye shielding during @entity348 to decrease @entity231 formation, 49 did not. The blocks used for shielding caused cylindrical areas of decreased dose intensity in the brain. The aim of the study was to determine if there was an increased risk of @entity735 or in the CNS after shielding of the eyes. The probability and severity of @entity231 formation with and without shielding were also evaluated. None of the 49 @entity1 without shielding had a relapse in their eyes or in the CNS after BMT. Of the @entity1 with shielding, none had a @entity735 but two of the 139 (1.4%) had a CNS relapse. The incidence of @entity231 without shielding was 90% (19 of 21 evaluable @entity1 ), while with shielding it was 31% (20 of 64). Severe @entity231 were present in eight of 21 (38%) @entity1 without and two of 64 (3%) @entity1 with shielding. The probability of staying @entity231 free for at least five years was 0.77 with and 0.33 without shielding, at 8 years it was 0.53 and 0.24 respectively. The relative risk of developing a @entity231 without shielding vs shielding was three (95% CI=1.5; 5.9). It appears that the incidence of @entity735 and CNS is not increased when the eyes are shielded during @entity348 . Shielding increased the latency time of @entity231 formation and decreased the severity of @entity231 .

title: Eye shielding during @entity348 for bone marrow transplantation in XXXX transplanted for a @entity1503 : risks and benefits.

answer: @entity1 :: (9606,Species) :: ['children']


abstract: PURPOSE: We determined the outcome of minimally symptomatic adult @entity4145 in a group of @entity1 treated conservatively with an active surveillance regimen. MATERIALS AND METHODS: A total of 27 @entity1 with asymptomatic or minimally symptomatic @entity4145 were treated conservatively. All @entity1 were evaluated with diuretic renograms. @entity4145 was defined by an obstructive pattern of the clearance curve and/or T1/2 greater than 20 minutes. Followup consisted of an office visit and renogram every 6 to 12 months. Cases of greater than 10% loss of relative renal function of the affected kidney, development of @entity2885 and/or more than 1 episode of acute @entity158 were considered active surveillance failures, and treatment was recommended. RESULTS: Of the 27 @entity1 6 were lost to followup, leaving 21 (median age 47 years) with sufficient followup for analysis. In the 4 @entity1 (19%) who initially presented with mild @entity158 that led to the diagnosis of @entity4145 , the @entity158 completely resolved. Ipsilateral relative renal function decreased significantly in 2 @entity1 (9.5%, mean reduction 14%). @entity158 worsened in 3 @entity1 (14.3%) and de novo @entity158 occurred in 1 (4.7%). Surgical intervention for @entity4145 was required in 6 @entity1 (29%) at an average of 34 months. In total 15 @entity1 (71%) remained on surveillance with a mean followup of 48 months. CONCLUSIONS: Active surveillance seems to be a reasonable initial option for asymptomatic or mildly symptomatic adult @entity1 with @entity4145 because only approximately 30% have progression to surgical intervention within 4 years of diagnosis. This strategy offers the advantage of individualizing therapy according to symptoms and renographic findings.

title: Intermediate term outcomes associated with the surveillance of XXXX in adults.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity2885 :: ('MESH:D011704', 'Disease') :: ['pyelonephritis']

entities_list: @entity4145 :: ('MESH:C537373', 'Disease') :: ['ureteropelvic junction obstruction', 'Ureteropelvic junction obstruction']

answer: @entity4145 :: (MESH:C537373,Disease) :: ['ureteropelvic junction obstruction']